Sarcomas

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

R. Lor Randall, MD, FACS, discusses the importance of orthopedic oncology consensus meetings and the need for agreement about certain surgical practices.

High variability in sarcoma clinical trial funding, location, and phase was identified in a global analysis conducted over the past decade.

In this episode, experts discuss the latest advancements in the multimodal treatment of undifferentiated pleomorphic sarcoma of the extremities.

The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.

Neeta Somaiah, MD, details challenges that are associated with pathology diagnosis, NGS, and early opinions for patients with sarcomas.

Phase 1b data support further exploration of intravenous sirolimus in patients with malignant PEComa.

R. Lor Randall, MD, FACS, discusses how immunodeficient mouse models support mechanistic and therapeutic discovery in rare sarcoma subtypes.

Frozen section analysis may be better reserved for high-risk tumor resections, as routine use shows limited benefit and increases cost, survey suggests.

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

Findings from the safety review of SON-1010 plus trabectedin in patients with advanced leiomyosarcoma or liposarcoma were positive.

Nivolumab plus sunitinib displayed early-phase efficacy in advanced bone sarcoma.

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Neeta Somaiah, MD, discusses chemotherapy as the current mainstay of treatment in sarcoma subtypes and the emergence of immunotherapies in the space.

OH2 monotherapy was safe and treatment with the agent led to responses in combination with HX008 in locally advanced or metastatic sarcoma.

A panelist discusses how T-cell receptor (TCR) therapies are likely to evolve through innovations such as allogeneic approaches, enhanced manufacturing processes, identification of new target antigens, and potential combinations with other immunotherapies, which could expand their applicability across multiple sarcoma subtypes and other solid tumors while improving accessibility and efficacy.